In vivo effect of recombinant human granulocyte colony-stimulating factor on neutrophilic expression of CD11b in septic neonates: A randomized controlled trial

Pediatric Hematology and Oncology

Volumn 29, Issue 3, 2012, Pages 272-284

  El Ganzoury, Mona M ^a   El Farrash, Rania A ^a   Saad, Abeer A ^a   Mohamed, Ashraf G ^b   El Sherbini, Inji G ^b  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

CD11b; Neonatal sepsis; Neutropenia; Recombinant human granulocyte colony stimulating factor

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CD11B ANTIGEN; GENELEUKIM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIGEN EXPRESSION; ARTICLE; BLOOD CELL COUNT; BLOOD CULTURE; BONE MARROW CELL; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION TEST; LABORATORY TEST; LEUKOCYTE COUNT; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; NEUTROPHIL COUNT; NEWBORN; NEWBORN SEPSIS; RANDOMIZED CONTROLLED TRIAL;

ANTI-BACTERIAL AGENTS; ANTIGENS, CD11B; BLOOD CELL COUNT; CELL PROLIFERATION; GRANULOCYTE COLONY-STIMULATING FACTOR; HOSPITALIZATION; HUMANS; INFANT, NEWBORN; NEUTROPHILS; SEPSIS; TREATMENT OUTCOME;

EID: 84859476431     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2011.644880     Document Type: Article

References (42)

1. Banerjea MC, Speer CP. The current role of colony-stimulating factors in prevention and treatment of neonatal sepsis [review]. Semin Neonatol. 2002;7:335-349. (Pubitemid 35238726)
2. Lewis DB, Wilson CB. Developmental immunology and role of host defenses in fetal and neonatal susceptibility to infection. In: Remington JS, Klein JO, eds. Infectious Diseases of the Fetus and Newborn Infant. 5th ed. Philadelphia: WB Saunders; 2001:25-138.
3. Urlichs F, Speer CP. Neutrophil function in preterm and term infants. NeoRev. 2004;5:e417-e430.
4. Gathwala G, Bala H. Colony stimulating factors as adjunctive therapy in neonatal sepsis. Indian J Pediatr. 2006;73:393-394. (Pubitemid 44319478)
5. Bedford Russell AR, Emmerson AJ, Wilkinson N, et al. A trial of recombinant human granulocyte colony stimulating factor for the treatment of very low birthweight infants with presumed sepsis and neutropenia. Arch Dis Child Fetal Neonatal Ed. 2001;84:F172-F176. (Pubitemid 32411255)
6. Schulz, KF, Altman DG, Moher D; CONSORT, Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152:726-732.
7. Elghetany MT, Lacombe F. Physiologic variations in granulocytic surface antigen expression: impact of age, gender, pregnancy, race, and stress. J Leukoc Biol. 2004;75:157-162. (Pubitemid 38174572)
8. Drossou-Agakidou V, Kanakoudi-Tsakalidou F, Sarafdis K, et al. Administration of recombinant human granulocyte-colony stimulating factor to septic neonates induces neutrophilia and enhances the neutrophil respiratory burst and beta2 integrin expression. Results of a randomized controlled trial. Eur J Pediatr. 1998;157:583-588. (Pubitemid 28311488)
9. Murray NA, Roberts IA. Neonatal transfusion practice. Arch, Dis Child, Fetal Neonatal, Ed. 2004;89:F101-F107. (Pubitemid 38338804)
10. Luban NL. Neonatal red blood cell transfusions. Curr Opin Hematol. 2002;9:533-536. (Pubitemid 35191125)
11. Töllner U. Early diagnosis of septicemia in the newborn. Clinical studies and sepsis score. Eur J Pe-diatr. 1982;138:331-337. (Pubitemid 12041564)
12. Manroe BL, Weinberg AG, Rosenfeld CR, Browne R. The neonatal blood count in health and disease. I. Reference values for neutrophilic cells. J Pediatr. 1979;95:89-98. (Pubitemid 9183688)
13. Adib M, Ostadi V, Navaei F, et al. Evaluation of CD11b expression on peripheral blood neutrophils for early detection of neonatal sepsis. Iran J Allergy Asthma Immunol. 2007;6:93-96. (Pubitemid 47203954)
14. Kocherlakota P, La Gamma EF. Human granulocyte colony-stimulating factor may improve outcome attributable to neonatal sepsis complicated by neutropenia. Pediatrics. 1997;100:E6. PMID: 9200380 [PubMed-indexed for MEDLINE].
15. Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled mul-ticenter trial. Am J Respir Crit Care Med. 2009;180:640-648.
16. Russell JA. Management of sepsis. N Engl J Med. 2006;355:1699-1713. (Pubitemid 44583960)
17. Carlet J, Cohen J, Calandra T, et al. Sepsis: time to reconsider the concept. Crit Care Med. 2008;36:964-966.
18. Monneret G, Venet F, Pachot A, Lepape A. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med. 2008;14:64-78. (Pubitemid 351356886)
19. Schefold JC, Hasper D, Volk HD, Reinke P. Sepsis: time has come to focus on the later stages. Med Hypotheses. 2008;71:203-208.
20. Pugin J. Immunostimulation is a rational therapeutic strategy in sepsis. Novartis Found Symp. 2007;280:21-27; discussion, 27-36, 160-164.
21. Hoesel LM, Gao H, Ward PA. New insights into cellular mechanisms during sepsis. Immunol Res. 2006;34:133-141. (Pubitemid 43997966)
22. Hubel K, Dale DC, Liles WC. Terapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma. J Infect Dis. 2002;185:1490-1501. (Pubitemid 34507973)
23. Gillan ER, Christensen RD, Suen Y, et al. A randomized, placebo-controlled trial of recombinant human granulocytecolony-stimulating factor administration in newborn infants withpresumed sepsis: signifcant induction of peripheral and bone marrow neutrophilia. Blood. 1994;84:1427-1433
24. Küçükodük S, Sezer T, Yildiran A, Albayrak D. Randomized, double-blinded, placebo-controlled trial of early administration of recombinant human granulocyte colony-stimulating factor to non-neutropenic preterm newborns between 33 and 36 weeks with presumed sepsis. Scand J Infect Dis. 2002;34:893-897.
25. Ahmad A, Laborada G, Bussel J, Nesin M. Comparison of recombinant granulocyte colony-stimulating factor, recombinant human granulocyte-macrophage colony-stimulating factor and placebo for treatment of septic preterm infants. Pediatr Infect Dis J. 2002;21:1061-1065. (Pubitemid 35334516)
26. Lehrnbecher T. [Hematopoietic growth factors in prevention and therapyof infectious complications in premature and newborn infants]. Z Geburtshilfe Neonatol. 2001;205:167-173. (Pubitemid 33043597)
27. Bo L, Wang F, Zhu J, et al. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care. 2011; 15:R58. PMID: 21310070 [PubMed-indexed for MEDLINE] PMCID: PMC3221991.
28. Schefold JC. Immunostimulation using granulocyte-and granulocyte- macrophage colony stimulating factor in patients with severe sepsis and septic shock. Crit Care. 2011;15:136. PMID: 21489333 [PubMed-in process] PMCID: PMC3219352 [Available on 2012/3/31].
29. Carr R, Brocklehurst P, Dore CJ, Modi N. Granulocyte-macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomised controlled trial. Lancet. 2009;373:226-233.
30. Torossian A, Ruehlmann S, Middeke M, et al. Deleterious efects of mild hypothermia in septic rats are ameliorated by granulocyte colony-stimulating factor. Anesthesiology. 2003;99:1087-1092. (Pubitemid 37339453)
31. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328-340.
32. Rosenbloom AJ, Linden PK, Dorrance A, et al. Efect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients. Chest. 2005;127:2139-2150.
33. Reddy RC, Chen GH, Tekchandani PK, Standiford TJ. Sepsis-inducedimmunosup pression: frombad to worse. Immunol Res. 2001;24:273-287. (Pubitemid 33064386)
34. Nupponen I, Andersson S, Järvenpää AL, et al. Neutrophil CD11b expression and circulating interleukin-8 as diagnostic markers for early-onset neonatal Sepsis. Pediatrics. 2001;108:E12. PMID: 11433091 [PubMed-indexed for MEDLINE].
35. Weirich E, Rabin RL, Maldonalda Y, et al. Neutrophil CD11b expression as a diagnostic marker for early-onset neonatal infection. J Pediatr. 1998;132(3 Pt 1):445-451. (Pubitemid 28180248)
36. Miura E, Procianoy RS, Bittar C, et al. A randomized double-masked, placebo-controlled trial of re-combinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early onset sepsis. Pediatrics. 2001;107:30-35. (Pubitemid 32055411)
37. Makhlouf RA, Doron MW, Bose CL, et al. Administration of granulocyte colony-stimulating factor to neutropenic low birth weight infants of mothers with preeclampsia. J Pediatr. 1995;126:454-456.
38. Russell AR, Davies EG, Ball SE, Gordon-Smith E. Granulocyte colony stimulating factor treatment for neonatal neutropenia. Arch Dis Child Fetal Neonat Ed. 1995;72:F53-F54.
39. Roberts I, Murray NA. Neonatal thrombocytopenia: causes and management. Arch, Dis Child, Fetal Neonatal, Ed. 2003;88:F359-364. (Pubitemid 37094251)
40. Schibler KR, Osborne KA, Leung LY, et al. A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis. Pediatrics. 1998;102(1 Pt 1):6-13. (Pubitemid 28309238)
41. Carr R, Modi N, Doré C. G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane, Database Syst, Rev. 2003;(3):CD003066.
42. Kuhn P, Messer J, Paupe A, et al. A multicenter, randomized, placebo-controlled trial of prophylactic recombinant granulocyte-colony stimulating factor in preterm neonates with neutropenia. JPediatr. 2009;155:324-330, e321.